drugset / Trial / NCT05634824
IVIg Plus Low Dose rhTPO for ITP in Pregnancy
RandomizedParallel-groupSingle-blindTreatment
Summary
Randomized, open-label, multicenter study to investigate the efficacy and safety of IVIg plus low-dose recombinant thrombopoietin in pregnant patients with corticosteroid or IVIg monotherapy-resistant ITP.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 400 mg/kg | Intravenous |
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 150 iu/kg | Subcutaneous |